TY - JOUR
KW - extended‐release injectable naltrexone
KW - opioid use disorder
KW - Literature Review
KW - Systematic Review
KW - Human
KW - Drug Therapy
KW - Substance use disorder
KW - Opiates
KW - Naltrexone
KW - Substance use treatment
KW - article
KW - 3383:Drug & Alcohol Rehabilitation
AU - Brantley P. Jarvis
AU - August F. Holtyn
AU - Shrinidhi Subramaniam
AU - D. A. Tompkins
AU - Emmanuel A. Oga
AU - George E. Bigelow
AU - Kenneth Silverman
A1 - 
AD - Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, US brantley.p.jarvis.ctr@mail.mil; Department of Psychiatry, University of California, San Francisco School of Medicine, San Francisco, CA, US ; Battelle Memorial Institute, Baltimore, MD, US ; Jarvis, Brantley P.,46020 Manekin Plaza, Suite 180,Dulles,US,20166,NorthTide Group, LLC,brantley.p.jarvis.ctr@mail.mil
BT - Addiction
C5 - Healthcare Disparities; Opioids & Substance Use
CP - 7
DO - 10.1111/add.14180
IS - 7
JF - Addiction
LA - English
M1 - Journal Article
PB - Wiley-Blackwell Publishing Ltd. Blackwell Publishing
PY - 2018
SN - 0965-2140, 0965-2140
SP - 1188
EP - 1209
EP - 
T1 - Extended‐release injectable naltrexone for opioid use disorder: A systematic review
T2 - Addiction
TI - Extended‐release injectable naltrexone for opioid use disorder: A systematic review
U1 - Healthcare Disparities; Opioids & Substance Use
U3 - 10.1111/add.14180
VL - 113
VO - 0965-2140, 0965-2140
Y1 - 2018
Y2 - 07
ER -